51.1 F
New York
Monday, November 28, 2022

Date:

Share:

Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer

Related Articles

ClinicalPURSUIT Offers Free Demonstration to Help Clinical Research Understand Their System and How It Can Help During Clinical Trials

Clayton, MO, November 25, 2022 --(PR.com)-- Clinical trials are expensive to conduct but are also essential in modern medicinal and therapeutic development. There is a...

ClinicalPURSUIT’s Software Offers Interactive Randomization Technology and RTSM to Help Researchers Conduct Flawless Clinical Research

Clayton, MO, November 25, 2022 --(PR.com)-- Clinical trials are crucial to developing modern medicines and therapeutic treatments. These research and trials are expected to be...

ClinicalPURSUIT’s Configurable Dashboards Assists Researchers in Conducting Clinical Research

Clayton, MO, November 25, 2022 --(PR.com)-- Clinical trials are fundamental to the success of modern medicinal and therapeutic development. However, there is a great need...

AACHEN, Germany, 22 November 2022 – Grünenthal today announced that Janneke van der Kamp will join Grünenthal as the new Chief Commercial Officer (CCO), effective 1 March 2023. Janneke van der Kamp joins Grünenthal from Novartis, where she most recently served as Head of Pharma Region Europe. The Dutch native brings broad experience in the pharmaceutical industry from several roles including General Manager, Global Neurosciences Franchise Head and Global Head of Product and Portfolio Strategy for the entire Novartis Pharma portfolio. She worked closely with Research & Development and the Licensing & Acquisitions teams to strengthen the company’s pipeline. Janneke van der Kamp has vast expertise in launching and growing key brands across several disease areas. She is a studied chemist and holds an MBA from INSEAD.

As CCO of Grünenthal, Janneke van der Kamp will be responsible for the entire Global Commercial Organisation and…

Read more…

Popular Articles